top of page

C2i and ANU Join Forces in Vaccine Development and Biotechnology


The Centre for Immunology & Infection Limited (C2i) and the Andong National University (ANU), Republic of Korea, have signed a memorandum of understanding aimed at fostering business collaborations and facilitating academic exchanges in the fields of vaccine development and biotechnology.

 

The agreement was signed by Professor Leo Poon, Managing Director of the Centre for Immunology & Infection, and Professor Sun-Woo Yoon, Project Coordinator of the Glocal University Project Group at ANU.

 

The collaborative efforts initiated by Professor Mark Zanin (C2i) and Professor Sun-Woo Yoon (ANU) seek to leverage the expertise and resources of both institutions to accelerate advancements in vaccine research and development, as well as promote knowledge exchange in the field of biotechnology. This partnership marks a significant milestone in the pursuit of scientific breakthroughs and the global fight against infectious diseases.

 

C2i and ANU will engage in joint research projects, sharing their knowledge and technical capabilities to drive innovations in vaccine development. The collaboration will also involve the exchange of personnel and students, fostering a vibrant academic environment that encourages cross-pollination of ideas and expertise.

 

Professor Leo Poon expressed his enthusiasm for the partnership, stating, “By pooling our resources and expertise, we hope to accelerate the development of effective vaccines and contribute to global health security. This partnership will provide unique opportunities for students and researchers to gain valuable insights."

 

By combining their strengths, C2i and ANU are poised to make significant contributions to the scientific community and society as a whole.


Professor Leo Poon, Managing Director of the Centre for Immunology & Infection (left), and Professor Sun-Woo Yoon, Project Coordinator of the Glocal University Project Group at ANU (right)

Comments


  • Threads
  • YouTube
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter
bottom of page